Molecular Imaging
Group Leader:
Prof David Lewis
Our lab focuses on understanding cancer as a metabolic disease, using molecular and total-body PET imaging to map how tumours use, compete for, and rewire nutrients across scales. We combine advanced cancer models, novel radiotracers, and quantitative image analysis to characterise metabolic phenotypes from single cells and tumour subregions through to whole-body physiology. By linking imaging signatures to genetics, microenvironmental context, and treatment response, we aim to uncover metabolic vulnerabilities that can be targeted to improve outcomes for patients.
A central theme of our work is the metabolic interplay between tumours and the host. We investigate how tumours reprogram their metabolism under therapeutic pressure, how distinct metabolic states contribute to drug and radiotherapy resistance, and how systemic conditions such as cancer cachexia develop. Through total-body PET, we visualise these processes in vivo. Our programs span mechanistic studies in GEMMs and organoids, development of novel PET tracers, and translational imaging trials across radiotherapy and systemic therapies.

Lab Reports

Recent Publications

Lab Members
Recent Publications
2026
Raffo-Iraolagoitia, X.L., Alyamani, A., May, S. et al. Multiscale in vivo imaging of tumor evolution using a germline conditional triple-reporter mouse. Nat Biotechnol (2026).
Maria Francesca Allega et al. ,Steroid-dependent metabolic rewiring reveals novel therapeutic and imaging approaches for glioblastoma.Sci. Adv.12,eadx6539(2026).
Williams, H.L., Poulain, N., Powley, I. et al. Spatial Molecular Plasticity Underpins Lethal Morphologies in Lung Adenocarcinoma. Modern Pathology 39, 03 (2026).
2025
Shaw, R.C., Morgan, T.E.F., McErlain, H. et al. Assessment of a 6-arylaminobenzamide lead derivative as a potential core scaffold for S1P5 positron emission tomography radiotracer development. Bioorg Med Chem119, 118057 (2025).
Müller, M., May, S., Hall, H., Kendall, T. J., McGarry, L., Blukacz, L., Nuciforo, S., Georgakopoulou, A., Jamieson, T., Phinichkusolchit, N. (2025). Human-correlated genetic models identify precision therapy for liver cancer. Nature.
Sushentsev, N., Hamm, G., Manavaki, R., McLean, M. A., Birchall, J., Soloviev, D., Lewis, D. Y., Aloj, L., Flint, L., Zakirov, A.(2025). Spatial metabolomics informs the use of clinical imaging for improved detection of cribriform prostate cancer. Proceedings of the National Academy of Sciences.122 (26), e2502423122.
2024
Malviya, G., Lannagan, T. R. M., Johnson, E., Mackintosh, A., Bielik, R., Peters, A., Soloviev, D., Brown, G., Jackstadt, R., Nixon, C. (2024). Noninvasive stratification of colon cancer by multiplex PET imaging. Clinical Cancer Research. 30 (8), 1518-1529.
2023
Dzien, P., Mackintosh, A., Malviya, G., Johnson, E., Soloviev, D., Brown, G., Uribe, A. H., Nixon, C., Lyons, S. K., Maddocks, O. (2023). Positron emission tomography imaging of the sodium iodide symporter senses real-time energy stress in vivo. Cancer & Metabolism. 11 (1), 14.
Ferrer, M., Anthony, T. G., Ayres, J. S., Biffi, G., Brown, J. C., Caan, Bette J; Feliciano, E. M. C., Coll, A. P., Dunne, R. F., Goncalves, M. D. (2023). Cachexia: A systemic consequence of progressive, unresolved disease. Cell. 186 (9),1824-1845.
2021
Najumudeen, A. K., Ceteci, F., Fey, S. K., Hamm, G., Steven, R. T., Hall, H., Nikula, C. J., Dexter, A., Murta, T., Race, A. M. (2021). The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer. Nature Genetics. 53 (1), 16-26.
2018
Lewis, D. Y., Mair, R., Wright, A., Allinson, K., Lyons, S. K., Booth, T., Jones, J., Bielik, R., Soloviev, D., Brindle, K. M. (2018) [18F] fluoroethyltyrosine-induced Cerenkov Luminescence Improves Image-Guided Surgical Resection of Glioma.Theranostics.8 (14), 3991.
2015
Lewis, D. Y., Soloviev, D., Brindle, K. M. (2015). Imaging tumor metabolism using positron emission tomography. Cancer Journal (Sudbury, Mass.). 21 (2), 129-136.
2014
Lewis, D. Y., Boren, J., Shaw, G. L., Bielik, R., Ramos-Montoya, A., Larkin, T. J., Martins, C. P., Neal, D. E., Soloviev, D., Brindle, K. M. (2014). Late imaging with [1-11C] acetate improves detection of tumor fatty acid synthesis with PET. Journal of Nuclear Medicine. 55 (7), 1144-1149.
Principal Scientific Officer
Emma Brown
As part of my role in the lab, I ensure the efficient running of the Translational Molecular Imaging facility and engage in multiple collaborative projects within the CRUK SI and further afield. My research interests surround the use of molecular imaging to non-invasively probe tumour evolution, and the biological validation of in vivo imaging signals. As part of Team CANCAN, a Cancer Cachexia Cancer Grand Challenge, I apply broad knowledge of molecular imaging and mouse models to use pre-clinical PET/MRI to probe systemic changes in metabolism during tumour development and cancer cachexia.
Translational GMP Radiochemist
Valeria Burianova
Research Radiochemist
Gavin Brown
As a research radiochemist, I develop radiochemistry methods and techniques to produce radiotracers for application in PET imaging studies. I have experience in using both commercial and custom-built radiochemistry platforms to produce radiotracers for clinical and preclinical PET research in accordance with GMP guidelines and under local quality management systems. Positron-emitting radionuclides used include carbon-11, fluorine-18, zirconium-89, iodine-124, copper-64 and gallium-68.
Head of Radiochemistry
Dmitry Soloviev
As Head of Radiochemistry, I lead radiochemistry efforts supporting PET imaging studies across Scotland, driving innovation in molecular imaging. My team has extensive expertise in radiopharmaceutical development, short-lived positron-emitting radionuclides, and advanced radiolabelling techniques. We specialize in radiolabelling metabolites to uncover cancer biochemistry and the interplay between disease biology and imaging.
By advancing preclinical and clinical PET studies, we help researchers translate discoveries into real-world impact.
Senior Preclinical PET Imaging Scientist
Stephen Paisey
I am a preclinical imaging specialist with 19 years of experience, built upon a background in synthetic inorganic chemistry and radiochemistry. I lead and collaborate on research programmes that apply advanced imaging technologies, including total-body preclinical PET/CT and 7T MRI, to address complex biological questions. As part of my role, I am establishing a radiometal and radiobiology laboratory focused on developing 89Zr radiolabelling methods for biologically derived agents, such as antibodies and cells, enabling the long-term in vivo tracking of emerging biological therapies.
Principal Scientific Officer
Robert Bielik
I am a PET imaging scientist interested in tumour metabolism. I study the causes and consequences of metabolic heterogeneity in lung cancer and investigate how tumours utilise nutrients such as glucose and acetate across time and multiple scales. I combine multiplexed PET imaging, isotope tracing, omics, mass spectrometry imaging, and spatial biology to uncover metabolic vulnerabilities and guide new therapeutic strategies. In my role, I drive research innovation, provide specialist scientific expertise, support group operations, co-supervise students, and foster internal and external collaborations.
PET Research Development Manager
Una Goncin
I leverage extensive expertise in project management, multimodal imaging, clinical trial management, and communications to drive the growth and impact of PET research in Glasgow. In my role, I lead the development, implementation, and oversight of PET imaging strategy, ensuring operational excellence, resource optimisation, and regulatory My role includes building collaborations, supporting and securing research funding, and creating opportunities for translational success. I lead marketing and outreach initiatives to raise the profile of PET research and ensure its long-term sustainability.
Senior Scientific Officer


